

Review of: "Ayurveda & Bioactives as Adjuvant for Dna Modulation in Cancer Treatment & Adverse Drug Reaction [ADR] – A Glimpse of Traditional Indian Nanotechnology"

Priyanka Kriplani

Potential competing interests: No potential competing interests to declare.

In the abstract, it is written that only 50% of patients face ADR upon cancer treatment, which is a vague sentence.

In the main body of the manuscript, only one case is discussed.

Rest all is discussed in the discussion section.

Sections are not interlinked; first, synthetic drugs and their ADR must be mentioned, and then move to herbal formulations, proving their efficacy in quantitative terms.

The author is describing synthetic drugs and herbal drugs, indicating insufficient results about their efficacy to treat cancer. Quantitative data must be given in terms of how much they inhibited the growth of cancer cells, IC50 values.

It doesn't contain any novel information.

Overall, the data presentation must be improved.